Search results for "bacille Calmette-Guerin"

showing 2 items of 2 documents

Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens

2006

Abstract Mycobacterium tuberculosis infects one-third of the global population and claims two million lives every year. Because memory CD8 T cells exhibit a high heterogeneity in terms of phenotype and functional characteristic, we investigated the frequency, phenotype, and functional properties of Ag85A epitope-specific HLA-A*0201 CD8 T cells in children affected by tuberculosis (TB) before and 4 mo after chemotherapy and healthy contact children. Using Ag85A peptide/HLA-A*0201 pentamer, we found a low frequency of blood peptide-specific CD8 T cells in tuberculous children before therapy, which consistently increased after therapy to levels detected in healthy contacts. Ex vivo analysis of…

MalePore Forming Cytotoxic ProteinsLEPROSYImmunologyEpitopes T-LymphocyteCD8-Positive T-LymphocytesBiologyTuberculinTUBERCULOSISEpitopeImmunophenotypingInterferon-gammaInterleukin 21Immune systemImmunophenotypingAntigenT-Lymphocyte SubsetsHLA-A2 AntigenHumansBACILLE CALMETTE-GUERINImmunology and AllergyCytotoxic T cellLymphocyte CountChildTuberculosis PulmonaryAntigens BacterialMembrane GlycoproteinsIFN-GAMMACOMPLEXHLA-A AntigensPerforinHIGH-FREQUENCIESMycobacterium tuberculosisINTRACELLULAR INFECTIONNatural killer T cellVirologyBOVIS BCGMICEChild PreschoolTuberculosis MeningealImmunologyFemaleImmunologic MemoryCD8RESPONSES
researchProduct

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

2017

International audience; TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, …

TuberculosiImmunologybacille Calmette–Guérin610 Medicine & healthReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesTuberculosis; Bacille Calmette-Guérin; Vaccination; Biomarker; Clinical trial; Portfolio management; Discovery[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Immunology and AllergyBacille Calmette-Guérinbacille Calmette-Guérinbacille Calmette-Guerin2403 Immunology10179 Institute of Medical MicrobiologyBacille Calmette-Guérin; Biomarker; Clinical trial; Discovery; Portfolio management; Tuberculosis; Vaccination; Immunology and Allergy; Immunologyclinical trialvaccination[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticstuberculosis2723 Immunology and Allergy570 Life sciences; biologybiomarkerportfolio managementdiscovery
researchProduct